Pulmonary arterial hypertension in a patient with β-thalassemia intermedia and reversal with infusion epoprostenol then transition to oral calcium channel blocker therapy: Review of literature

Kamonpun Ussavarungsi, Charles D. Burger

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

Pulmonary arterial hypertension (PAH) is a potentially life-threatening complication of thalassemia. A sexagenarian with β-thalassemia intermedia presented with new-onset dyspnea and syncope. Right heart catheterization confirmed severe PAH. Her functional class IV symptoms and severely elevated mean pulmonary artery pressure prompted the initiation of continuous epoprostenol therapy. Clinical follow-up documented significant improvement in functional class, 6-minute walk distance, and right ventricular size and function as well as pulmonary arterial pressure on echocardiogram. At the patient’s request, epoprostenol was down-titrated and eventually discontinued. The patient was then safely transitioned to nifedipine therapy after verification of vasoresponsiveness.

Original languageEnglish (US)
Pages (from-to)520-526
Number of pages7
JournalPulmonary Circulation
Volume4
Issue number3
DOIs
StatePublished - Sep 2014

Keywords

  • Epoprostenol treatment
  • Pulmonary arterial hypertension
  • Pulmonary hypertension
  • β-thalassemia intermedia

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Pulmonary arterial hypertension in a patient with β-thalassemia intermedia and reversal with infusion epoprostenol then transition to oral calcium channel blocker therapy: Review of literature'. Together they form a unique fingerprint.

Cite this